Schizophrenia: Early Recognition and Prevention by Podea, Delia Marina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Schizophrenia: Early Recognition 
and Prevention
Delia Marina Podea, Romina Teodora Moldovan  
and Laura Cristina Popa
Abstract
Schizophrenia is a heterogenous disorder presenting as episodes of psy-
chosis against a background of cognitive, social, and functional impairments. 
Schizophrenia, a multifaceted neuropsychiatric disorder, is affecting approximately 
1% of the population worldwide. Its onset is the result of a complex interplay of 
genetic predisposition and environmental factors. The clinical staging model of 
psychotic disorders implies that early successful treatment may improve prognosis 
and prevent progression to more severe stages of disorder. So, prevention and early 
intervention of schizophrenia are correlated with the prodromal phase, especially 
with “at risk mental state” (ARMS) and the prediction of their transition to a 
full-blown psychotic disorder. The psychosis prodrome includes nonspecific signs 
and symptoms (such as depressed mood, anxiety, sleep disturbance, and deteriora-
tion in role functioning), “basic symptoms” (thought interference, disturbance of 
receptive language, and visual perception disturbance), attenuated or subthreshold 
psychotic symptoms, neurocognitive deficits, and neurobiological changes mea-
sured via magnetic resonance imaging (MRI). Increasing improvements in the 
identification of those truly at “high risk” for psychotic disorder have paved the way 
of early intervention strategies in this population and increased the possibility of 
minimizing distress and disability and delaying or even preventing the onset of an 
evident psychotic disorder. The treatment (antipsychotic medication, psychologi-
cal and social interventions) for young people who meet ARMS criteria should not 
only focus on the symptoms that constitute the ARMS criteria but also address the 
broader range of difficulties with which the young person might present. There are 
some ethical issues to consider when selecting specific treatment options, and the 
potential risks of treatment have to be balanced against the potential benefits.
Keywords: early recognition, clinical staging model, prodromal phase,  
at risk mental state, prevention
1. Introduction
Schizophrenia is a heterogenous disorder presenting as episodes of psychosis 
against a background of cognitive, social, and functional impairments.
Schizophrenia, a multifaceted neuropsychiatric disorder, is affecting approxi-
mately 1% of the population worldwide. Its onset is the result of a complex interplay 
of genetic predisposition and environmental factors.
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After more than 100 years of studies and clinical psychiatric practice, passing 
through numerous conceptualizations of psychosis and schizophrenia, research 
tries to achieve an evolutionary pattern of psychosis and to establish clear, distinc-
tive diagnostic criteria for every type of psychosis.
Psychosis is unanimously considered essential for understanding the evolution 
and treatment process and also for estimation of prognosis.
Recently, the area of “prodromal” research in schizophrenia and related dis-
orders has grown considerably. From initial retrospective studies of this phase, 
dating back to the early twentieth century, the last decade of the century has seen 
the beginning and expansion of prospective studies aiming to identify the earliest 
manifestations of psychotic illnesses. From identification of these prodromal or 
“ultrahigh-risk”(UHR) individuals, the area has also developed to include inter-
vention studies aiming to prevent, delay, or ameliorate the onset of a full-blown 
psychotic disorder and to investigate underlying processes that cause or contribute 
to the onset [1].
The fact that psychosis disorders, such as schizophrenia, begin with a prodromal 
phase prior to the onset of frank psychotic symptoms has been known since the first 
description of the illness was documented [1].
The pattern of psychosis and of the first episode of psychosis is similar to the 
pattern of schizophrenia but more complex.
Strauss and Carpenter considered that schizophrenia includes an interactive, 
developmental, and systematic model [2–6]. By analogy, the model of the first 
psychotic episode can be considered an interactive, developmental, and systematic 
model.
The arguments to sustain this theory (hypothesis) are:
1. Variables that interact either sequentially or simultaneously and are nonspe-
cific or partly known.
2. Genetic vulnerability is sometimes well known; in the first psychotic 
episode, there is a variety of genetic mechanisms with varying degrees of 
impact and strong expressiveness even from the prodromal or prepsychotic 
period. But for those with well-known genetic vulnerability, clinical expres-
sivity may be missing, and not everyone with genetic predisposition shows 
schizophrenia.
3. Perinatal factors may constitute an independent variable that increases the 
person’s vulnerability to develop a psychotic pathology, and when interacting 
with genetic and environmental factors, the risk increases both in schizophre-
nia and psychosis [7].
Due to the complexity and heterogeneity of the first psychotic episode, to 
conceive and to unanimously recognize it like a coherent and unitary model are 
extremely difficult. The unknowns of this huge puzzle are still numerous despite 
the scientific efforts.
The model of the first psychotic episode has a medium- or long-term impact on 
schizophrenia model and can be of particular relevance to both etiopathogenesis 
and treatment as well as prevention strategies.
Over the last years, the most exciting signs of progress in defining a new con-
ceptualization of psychosis are reported by the genomic studies [8, 9]. Maps of the 
neurobiological circuits of cognitive functions have been designed and have tried to 
explain the ways in which these circuits become dysfunctional in various disorders 
including the psychotic ones.
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2. Description of psychosis
Researchers from the National Institute of Mental Health (NIMH) have reported 
three conclusions:
1. Psychosis is a neurodevelopmental disorder, with onset in adolescence and 
period when the cortex is still in development.
2. For most disorders related to the cortical functions, the changes of cognitive 
and comportamental fields appear (occur) later, suggesting the existence of 
biological dysfunctions long before psychosis.
3. Psychosis like other complex diseases has a multifactorial determinism.
These data have facilitated the explanations of the pattern of psychosis by 
integrating molecular biology, neuroscience, and behavioral sciences. This new 
approach tries to discover finally the new treatment strategies including new 
medications (antipsychotics) and psychological, social, and other potential 
interventions.
The work group for psychosis within DSM-V proposes distinct clinical domains 
for each psychotic disorder correlated with the neuronal circuits [10].
In 2009 Jim van Os, one of the members of work group for psychosis, proposed 
a new syndrome named “salience dysregulation syndrome” as a diagnostic to be 
used [11].
Jim van Os used the psychotic model of Kapur who considers that hallucinations 
and delusional ideas appear because the individual has difficulties in recognizing 
his or her mental experience relevance. Jim van Os used the term syndrome not 
disease, because a syndrome is a set of symptoms that appear simultaneous with-
out having a common cause. The symptoms described are positive and negative 
symptoms, disorganization, developmental cognitive deficits, and depressive and 
maniacal symptoms [11].
The “salience dysregulation syndrome” was divided for diagnosis into:
a. “Salience dysregulation syndrome with developmental cognitive deficits”
b. “Salience dysregulation syndrome with affective expression”
c. “Salience dysregulation syndrome not otherwise specified” [11]
3. Attenuated syndrome
In 2010, Dominguez and collaborators [12] also members of work group for 
psychosis described two new innovative aspects:
• Deconstructing psychosis/schizophrenia disorganization considered as a 
syndrome.
• The attenuation of psychotic symptoms is a favorable predictor for the outcome.
In his study [12], Dominguez considered that the association of negative symp-
toms or of the disorganization with attenuated psychotic symptoms increases the 
risk of developing a psychotic frank syndrome.
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4. The prodrome
Although there is great variability between patients in how their prodromes 
manifest, certain symptoms and signs have been frequently described. These 
include depressed mood, anxiety, irritability and aggressive behavior, suicidal ide-
ation and attempts, and substance use. The most commonly occurring prodromal 
symptoms, according to retrospective studies of patients with schizophrenia and 
schizophreniform disorder, are reduced concentration and attention, reduced drive 
and motivation, depression, sleep disturbance, social withdrawal, suspiciousness, 
deterioration in role functioning, and irritability [1].
Studying these symptoms, we observe two things. First, many of them are 
nonspecific occurring frequently in the prodromes of nonpsychotic threshold 
syndromes. Second, a considerable amount of psychiatric symptoms, disability, 
self-harming, and other health-damaging behaviors, occur during this prodromal 
phase, even in the earliest stages [1, 19, 22, 39].
Cognitive, affective, and social disturbances known as “basic symptoms” are 
also commonly described in the early prodromal phases. This concept of “basic 
symptoms,” developed in the 1960s, has significantly influenced the new area of 
prodromal research [1].
5–10% of the general population experience attenuated or subthreshold form of 
psychotic symptoms like transient perceptual symptoms; suspiciousness; reference 
and bizarre delusional ideas (e.g., the beliefs that others may be thinking badly 
about or laughing at); nonattendance at school, university, or work; and altered 
behavior toward family and friends [1, 16].
The difference between these phenomena and clear psychotic symptoms is due 
to their intensity, frequency, duration, and deleterious effects on the individual 
functionality of the person.
Neurocognitive deficits in particular impaired attention, spatial and verbal 
memory, and speeded information processing are also evident in the prodromal 
phase but at a lower degree of severity comparing to those found in first-degree 
relatives of patients with schizophrenia or in fully affected patients [1].
Specific cognitive deficits may be related more directly to affected brain 
structures and candidate genes and so may be more directly predictive of 
psychosis.
5. Treatment
In the prodromal and in the onset phase of psychosis, neurobiological changes can 
be identified. During the process of transition to psychosis, magnetic resonance imaging 
(MRI) highlights significant bilateral reduction in gray matter volume in the cingulate 
region as well as in the left parahippocampal gyrus, left fusiform gyrus, left orbitofron-
tal cortex, and one region of the left cerebellar cortex [1]. It is important to notify that 
these brain changes were not present in the UHR group that did not develop psychosis.
The differentiation between normal and abnormal has important implications 
for defining the prodromal phase of schizophrenia and the therapeutic interven-
tions at this early stage. Atypical antipsychotics has improved the treatment and 
the outcome of schizophrenia and psychosis due to their low risk for adverse effects 
like extrapyramidal effects, tardive dyskinesia, sedation, weight gain, metabolic 
syndrome, amenorrhea, galactorrhea, sexual dysfunctions, etc.
Psychosocial interventions give optimism regarding the prognosis of disease by 
improving family and social difficulties, stigma avoidance, victimization, isolation, 
and poverty [13].
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If the prodrome can be recognized prospectively and treatment can be provided 
at this stage, then disability could be minimized, some recovery may be possible 
before symptoms and poor functioning become obvious, and the possibility of 
preventing is feasible and realistic. The early intervention aims:
• To slow or possibly to stop further deterioration and even further progression 
to psychosis.
• To reduce the poor functional outcome characterizing many vulnerable 
individuals, whether or not psychosis actually develops.
• To evaluate and prevent secondary morbidity in order to decrease morbidity 
and mortality in the first episode of psychosis.
• To create research opportunities to develop new therapeutic strategies.
• To develop secondary prevention strategies.
Early intervention has to take place in the three important phases of early 
psychosis:
a. In the phase of risk when the symptoms are subtle and can be confused with 
particularities and difficulties specific to adolescence.
b. In the period of frank psychosis in which if the symptoms remain untreated, 
there is a risk of temporal or permanent disability.
c. In the critical period after the onset of the first episode of psychosis, a period 
which can last up to 5 years after the onset, the length of time that treatment 
should be comprehensive and specific.
6. Redefining psychosis
The latest attempts redefining the concept of psychosis have focused particularly 
on the first episode of psychosis and on prodromal stage of schizophrenia.
Arguments for these new concepts can be synthesized as:
• Clinical heterogeneity of patients diagnosed with first psychotic episode.
• The heterogenous outcome of these patients.
• The instability of the diagnosis over time.
• Avoidance of negative prognostic.
• Stigma avoidance.
7. A history of prodrome: benefits of diagnosis of the prodrome
Over 100 years ago, Emil Kraepelin (1896), cited by Patrick McGorry at the 
beginning of the chapter “A stitch in time” [14], wrote “it is of the greatest medical 
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importance to diagnose cases of dementia praecox certainly and at an early stage” 
(Kraepelin, 1896/1987, p. 23).
In 1908, Eugen Bleuler, cited by Patrick McGorry in the same book [14], wrote 
“the sooner the patients can be recovered and the less they are allowed to with-
draw in their own world, the sooner they become socially functional” (Bleuler, 
1908/1987, p. 63).
Coming from 1927 [15], we find the same idea “I feel certain that many incipi-
ent cases might be arrested before the efficient contact with reality is completely 
suspended, and a long stay in institutions made necessary” ([15], p. 135). Meares 
in 1950 wrote “it is not necessary to diagnose early schizophrenia but to diagnose 
prepsychotic schizophrenia ,to prevent damage”.
These statements can be used not only as the foundation stones for any thera-
peutic intervention but also as arguments to emphasize the importance of early 
phases of psychosis.
8. Definition of prodrome
So, the prodrome is a distinct period in the evolution of the first psychotic epi-
sode, mostly unknown or minimized as importance. The onset’s particularities and 
the evolution of the first psychotic episode are involved in the short-, medium-, and 
long-term prognosis. The recovery depends on the early initiation of therapeutic 
strategies.
The prodrome was originally defined as the prepsychotic period preceding a 
relapse in patients already diagnosed with psychosis. Subsequently a distinction was 
made between the initial and the relapse prodrome [16].
Other definitions are [16]:
• “a heterogenous group of behaviors having a temporal relationship with 
psychosis’ onset”.
• “the period from the first symptoms noted until the onset of prominent 
psychotic symptoms”.
All definitions of prodrome phase have in common the presence of symptoms 
and the temporal relationship with the onset of psychosis, with two important prac-
tical consequences. The first implication is the person being symptomatic during 
the prodrome will ask for medical help, so it is possible to establish a diagnosis and 
a therapeutic strategy. The second implication is the person can develop the disease 
after the end of the prodromal phase, suggesting that the transition from prodrome 
to frank psychosis may be detectable.
9. False positives and treatment
However, early attempts at prodromal intervention were hampered, by the 
problem of “false positives” and their implications for preventive intervention. 
“False positives” refer to those who are identified as being prodromal, at risk of 
developing a psychotic disorder in the near future, but who do not do so. Some 
of these people were in fact never “destined” to develop a psychotic disorder (the 
“true false positives”) [1]. These persons may be harmed by being considered as 
“prodromal” or “high risk of psychosis” and may receive treatment unnecessarily 
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[17–19]. In contrast are those individuals who would have developed a psychotic 
disorder were it not for some alteration in their circumstances,such as a treatment 
intervention, stress reduction or cessation of illicit drug use, that preventing this 
form occurring [1]. This latter group has been termed “false false positive” [19]. It 
is virtually impossible to distinguish between these two groups phenotypically at 
baseline and follow-up.
10. Description of prodromal phase
The conceptualization of the prodrome phase uses two methods: a retrospec-
tive/passive method which involves getting information from the patient and his/
her family and a proactive one which includes observation and patient monitoring 
during psychosis.
Yung and McGorry [16] describe the phenomenology of the prodrome phase, 
summarizing the data from the literature with those of the Melbourne Personal 
Assessment and Crisis Evaluation (PACE) approach [20, 21]. The PACE Clinic 
recruits those patients with a perceived need for psychiatric help.
11. Ultrahigh risk
The PACE ultrahigh-risk (UHR) criteria require that a young person aged 
between 14 and 30 is referred for health care to the clinic if the criteria for one or 
more of the following groups are met:
1. Attenuated psychotic symptom (APS) group has experienced subthreshold, 
attenuated positive psychotic symptoms during the past year.
2. Brief limited intermittent psychotic symptom (BLIPS) group has experienced 
episodes of frank psychotic symptoms that have not lasted longer than a week 
and have spontaneously abated.
3. Trait and state risk factor group has a first-degree relative with a psychotic 
disorder or the identified subject with a schizotypal personality disorder and 
has experienced a significant decrease in functioning during the previous year 
[19, 22]
The ultrahigh-risk (UHR) criteria allow the recognition of young people at 
risk of onset of a psychotic disorder (late adolescence/early adulthood) who also 
report mental state disorder suggesting an emerging psychotic process or who 
may have a positive family history of psychosis accompanied by evidence of 
mental ill health.
Necessarily, criteria have also been developed to define the onset of frank 
psychosis. These are not identical to DSM-V criteria [22, 23] but are elaborated 
to define the minimal point at which antipsychotic treatment is indicated. 
This definition is arbitrary but even has a well-defined treatment implication, 
applicable equally to “substance-related symptoms, symptoms that have a mood 
component—either depression or mania—and schizophrenia spectrum disorders.” 
The predictive aim is the first-episode psychosis requiring antipsychotic treat-
ment, arbitrarily defined by the persistence of clear psychotic symptoms, more 
than 1 week [1, 19].
Neurodevelopment and Neurodevelopmental Disorder
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The intensity of psychotic symptoms characteristic for each of the UHR groups 
was firstly assessed using the following scales: the “Brief Psychiatric Rating Scale 
(BPRS) and the Comprehensive Assessment of Symptoms and History (CASH) 
interview.” To specify the frequency and duration of psychotic symptoms, new 
criteria were needed. So, a new instrument, the Comprehensive Assessment of At 
Risk Mental States (CAARMS) was designed so that all relevant domains (intensity, 
frequency, duration, and recency) could be assessed [1, 24].
The PACE UHR criteria have been adopted and adapted in a large number of 
other settings around the world (USA, UK, Norway, Germany, etc.).
Symptoms associated with prodromal phase.
Yung and McGorry [16] identified eight subtypes of symptoms characteristic of 
prodromal phase:
• Neurotic symptoms: anxiety, irritability, restlessness.
• Affective symptoms: depression, anhedonia, guilt, suicidal ideas, thymic 
oscillations.
• Volitional disturbances: apathy, loss of interest, low energy, fatigue.
• Cognitive deficits: attention deficit, rumination, abstraction difficulties, thought 
blockages, thought interference, thought perseveration, thought pressure.
• Psychotic symptoms: visual and auditory perceptual disturbances, suspicious-
ness or paranoid ideation, derealization, unstable ideas of reference.
• Physical symptoms: somatic symptoms, weight loss, low appetite, sleeping 
disorders.
• Behavioral dysfunctions: social withdrawal, impulsivity, aggressivity, bizarre 
behavior, functional deterioration.
• Other symptoms: sensitivity, odd beliefs or magical thinking, dissociation.
Yung and collaborators [19, 25] have elaborated a set of operational criteria 
to identify individuals at risk for developing a psychotic disorder over the next 
6–24 months as Global Assessment of Functioning (GAF) scale score <51, BPRS 
score >2, and Hamilton Depression Rating Scale (HRDS) score >18 [19, 25].
12. Risk factors to developing psychosis
During the years, several research teams have identified a number of risk factors 
for the development of psychosis: Carr and collaborators (2000): family history, 
perinatal complications, premorbid personality, stressful life events; Mason et al. 
[26]: schizotypal personality disorder, hallucinations, magic thinking, odd beliefs, 
anhedonia, withdrawal, functional deterioration [27].
13. Duration of prodrome
Regarding the duration of the prodrome, retrospective studies suggest a varia-
tion ranging from a short period to several years [7, 26, 28].
9Schizophrenia: Early Recognition and Prevention
DOI: http://dx.doi.org/10.5772/intechopen.88537
14. Genetic risk programs for psychosis
The development of genetic high-risk (GHR) programs was an important step 
for early detection and intervention, especially in schizophrenia.
In recent years, genetic research have identified specific genes for schizophrenia, 
some with early phenotypic expression may be considered important biomarkers, 
for example, the CHRNA7 gene situated on chromosome 15 with importance in 
genetic transmission and heredity of schizophrenia [29–32].
The phenotype “schizophrenia” has been characterized by the presence of 
behavioral abnormalities, the related outcome, and its longitudinal course, but not 
its fundamental biological substrate. The absence of a neuropathological basis for 
schizophrenia was one reason that some researchers supported the neurodevelop-
mental hypothesis of schizophrenia issued by Weinberger [33]. Evidence of obstet-
rical complications being associated with the risk of schizophrenia supported that 
developmental abnormalities were involved [34].
The premorbid risk factors associated with schizophrenia as motor and cognitive 
delay and obstetrical complications are nonspecific; their prevalence in the non-
affected population is important, so their positive predictive value for the develop-
ment of schizophrenia is limited.
Neuroimaging anomalies found in patients diagnosed with first-episode psycho-
sis have been interpreted as supportive of a static structural abnormality associated 
with schizophrenia that had originated early in neurodevelopment [35].
Recently, the association of molecular genetics with intermediate phenotypes 
such as cognitive impairment or abnormal brain functioning, as measured with 
functional neuroimaging, has generated diverse understanding of major psychosis. 
The combination of different levels may be of particular importance for longitudi-
nal “at risk” studies. These studies can identify individuals who are at true risk of 
developing major psychosis prior to its full clinical expression, enabling us to treat 
“at risk” individuals prior to full manifestation of psychosis and prevent its appear-
ance during critical developmental periods such as late adolescence [1, 36].
The measurement of genetic profiles using groups of candidate genes in com-
bination with psychosocial risk factors such as stress and illicit drug use in samples 
of patients with clinically significant but subthreshold features of psychosis and 
mood disorder is a key strategy in enhancing predictive power for transition to more 
established and severe psychotic disorders, in treatment selection, and in longer-
term prognosis [1].
Genetic studies suggest that diagnostic boundaries may be modified based on 
genetic information and some genes such as NRG1, DTNBP1, DISC1, and BDNF 
may relate to risk for both schizophrenia and mood disorders [37]. The synergistic 
use of genotyping with phenotypes characterizing brain functioning will contribute 
to a better understanding of the mechanisms by which genes interact with other 
genes and/or environmental risk factors.
15. Disadvantages of “prodromal” identification
Identification by different methods of people at risk of psychosis in the gen-
eral population has allowed an increase in accuracy from a rate of 1% to a rate 
of approximately 30% [1]. However, the increase in accuracy has raised some 
criticism. One is that the screening would not be effective in the general popula-
tion because of the lower base rate of psychotic illness in that population [38], so 
screening for UHR criteria would not be supported at this stage [19]. The second 
criticism is that there is a high false positive rate in all of these studies, the majority 
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of participants not developing psychotic disorder. Consequently, some persons 
will be “diagnosed” and treated as if they were at “high risk” of psychosis, when 
this may not be true. This false identification may have negative consequences on 
those individuals: they may become anxious or depressed about the possibility of 
developing schizophrenia or receiving treatment, stigmatized by others or them-
selves or both [39]. These people may be exposed to drug or other therapies, with 
potential adverse effects without gaining any benefit [39, 40–43]. This controversy 
on the risk benefit balance of early intervention strategies must be addressed by 
future studies.
16. Predictors of psychotic disorder in high-risk groups
Since 2004, many prospective programs focused on early psychoses have been 
developed.
The term “at risk mental state” (ARMS) is still used today to describe individuals 
at risk to develop a psychotic disorder [1, 44]. So, different diagnostic systems have 
been achieved, one of the most known and sophisticated systems being developed 
by McGorry and his team (1966) in order to reduce the number of “false positive” 
cases [1, 44]. The diagnostic system accomplished by McGorry et al. has three 
categories of diagnostic criteria for individuals’ “at risk mental state” (ARMS):
1. Attenuated psychotic symptoms (APS).
a. The presence of at least one of the following: ideas of reference, odd 
beliefs, magical thinking, perception disturbances, paranoid ideation, 
formal thought disorder, disturbances of receptive language.
b. Frequency of symptoms: several times a week.
c. Duration: have experienced subthreshold, attenuated positive psychotic 
symptoms during the past year.
d. Recently: stressful life events during the last year.
2. Brief limited intermittent psychotic symptoms group (BLIPS).
a. Transient psychotic symptoms: the presence of at least one of the fol-
lowing—ideas of reference, odd beliefs, magical thinking, perception 
disturbances, paranoid ideation, formal thought disorder, disturbances of 
receptive language.
b. Frequency of symptoms: few times a week.
c. Duration: less than a week and spontaneously abated.
d. Recently: short intermittent psychotic symptoms were present during the 
previous year.
3. Trait and state risk factor group.
a. First-degree relative with a psychotic disorder or the identified individual 
with a schizotypal personality disorder.
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b. Significant decline in functioning during the previous year.
c. Duration: at least 1 month and no more than 5 years [19, 22].
These criteria were criticized for the absence of negative symptoms of 
schizophrenia.
Cornblatt et al. mentioned, among the diagnostic criteria of the prodrome, 
negative attenuated symptoms or disorganization, which define clinical high-risk 
(CHR) group representing the early prodromal stage and CHRT group representing 
tardive prodromal stage [45]. CHRT group is characterized by negative attenuated 
symptoms, disorganization, and positive symptoms.
Negative symptoms are impaired concentration and attention, subjectively 
abnormal emotional experiences, blunted affect, impaired energy, and impaired 
tolerance to stress [24].
Marked impairment in role functioning, flat or inappropriate affect, anhedonia, 
and asociality were found at significantly higher levels at baseline in those who went 
on to develop psychosis than in those who did not [26]. So, negative symptoms have 
been found to be predictive of psychosis [1].
Positive symptoms like unusual thought content, suspiciousness, perceptual 
disturbance, conceptual disorganization, and disorganized communication are 
significant predictors of psychosis [19, 46, 47].
The ultrahigh-risk (UHR) criteria have been used and modified in different 
countries around the world: USA, UK, Germany, and Finland.
The German Research Network on Schizophrenia (GNRS), Cologne, Bonn, 
Düsseldorf, and Munich, introduced the basic symptoms into the definition on the 
prodrome [48, 49].
The basic symptoms included thought interferences, perseveration, pressure or 
blockages, and disturbances of receptive language; decreased ability to discriminate 
between ideas and perception or fantasy and true memories; unstable ideas of refer-
ence; derealization; and visual or auditory perceptual disturbances. Using these basic 
symptoms, it should be possible to identify subjects at risk of developing schizophre-
nia, and so early intervention is possible. Because basic symptoms were frequently 
found before any subthreshold or attenuated psychotic symptoms, these criteria 
were thought to be detecting the very beginning of the initial prodromal phase [50].
Unlike McGorry et al., the GNRS distinguishes between the “early initial 
prodromal state” (EIPS) and the “late initial prodromal state” (LIPS). The EIPS 
criteria attempt to define a group at incipient but not imminent or immediate risk of 
psychosis. The criteria consist of the 10 predictive basic symptoms of which one or 
more is required, plus the PACE trait and state risk UHR criterion.
16.1 The EIPS criteria
One or more of the following basic symptoms:
• Thinking disturbances: perseveration, pressure, blockage, ideas of reference 
(unstable)
• Disturbances of visual and auditory perception
• Disturbances of receptive language (either heard or read)
• Diminished capacity to discern between ideas and perception, fantasy, and 
true memory
Neurodevelopment and Neurodevelopmental Disorder
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16.2 Derealization
The onset of the symptoms has occurred at least a year ago, with a frequency of 
several times a week within the last 3 months.
• Decrease in “the Global Assessment Functioning Score” (DSM-V) of at least 30 
points in the past year which add one of the following risk factors: “first-degree 
relative with a lifetime diagnosis of schizophrenia or a schizophrenia spectrum 
disorder and/or pre- or perinatal complications”.
• The absence of attenuated or transient psychotic symptoms [1].
The LIPS criterion attempts to identify those at more immediate risk and is 
based on the APS and BLIPS criteria [51].
16.3 The LIPS criteria
• The presence of at least one of the following attenuated positive symptoms 
(APS) present within the last 3 months, appearing several times per week for a 
period of at least 1 week, but no longer in the same severity than 1 year: “ideas 
of reference; odd beliefs or magical thinking; unusual perceptual experiences; 
odd thinking or speech; suspiciousness or paranoid ideation”.
• “Brief limited intermittent psychotic symptoms (BLIPS), defined as appear-
ance of one of the following frank psychotic symptoms for less than 1 week 
(interval between episodes at least 1 week) and resolving spontaneously: 
hallucinations; delusions; formal thought disorder; gross disorganized or 
catatonic behaviour” [1].
This two-stage prodromal state guides the treatment approach, that is, psycho-
logical or pharmacological therapy [51–53]. LIPS criteria denote an imminent risk 
of transition to psychotic disorder within the next 12 months, so an antipsychotic 
medication—second generation—appeared justified. Psychological interventions 
were crisis intervention, psychoeducation, family counseling, and assistance with 
education or work-related difficulties.
In EIPS group the psychological intervention (cognitive behavioral therapy 
(CBT) or the supportive control condition) appeared successful in preventing 
further progression of the illness [54].
17. Early intervention and prevention
Early intervention may be able to delay or even prevent onset of psychosis in the 
UHR or prodromal stage. Both antipsychotic medication (risperidone 1–2 mg/day, 
olanzapine 5–15 mg/day) and psychological interventions (cognitive behavioral 
therapy (CBT), case management, supportive therapy, problem-solving strategies) 
might have a role in treating the difficulties and problems that UHR young people 
experience, as well as in reducing the rate of transition to psychosis and in reducing 
symptomatology. Deterioration in psychosocial functioning and persistent disabil-
ity is also an important treatment goal [1].
Therapeutic strategies must be personalized and correlated with the first psy-
chotic episode stages. Treatment for young people who meet ARMS criteria should 
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not only focus on the symptoms that constitute the ARMS criteria but also address 
the range of difficulties which the young person might present.
Side effects associated with all antipsychotic medications are weight gain, dia-
betes, and sexual dysfunction for olanzapine [55–57] and sexual dysfunction and 
insomnia for risperidone [1]. Extrapyramidal side effects such as tardive dyskinesia, 
which is often irreversible, are less common with the newer, atypical antipsychotics 
[58, 59]. Evidence also suggests that certain antipsychotics (haloperidol) reduced 
gray matter volume in the brains of patients with a first episode of psychosis [60]. 
In contrast the newer second-generation antipsychotic medications, in fact, have 
neuroprotective qualities.
Antipsychotic drugs are potentially useful in the latter phases of the prodromal 
period when attenuated psychotic symptoms are evident and the individual is on 
the edge of a conversion to full psychosis.
Psychological interventions are useful in earlier and less symptomatic stages 
of the prodrome, to manage the stress, depression, anxiety, sleep disturbance, 
and decline in functioning. CBT should be effective for people with attenuated 
psychotic symptoms or with brief limited intermittent psychotic symptoms and for 
individuals who are “false positives” [22].
Psychological treatments may be not only necessary but sufficient for some of 
these putatively prodromal patients [1].
Further researches are required to determine which treatment strategies are 
most effective and how long they should be continued.
Ethical considerations associated with treatment of young people who meet 
ARMS criteria have been widely debated [17, 28, 40, 41, 42, 45, 46]. Concerns about 
stigma associated with being identified as having a label of ARMS “false positives” 
and for how long should treatment be provided (in other words, how long is the 
period of risk) remain unresolved, and even clinical research into ARMS has now 
been conducted for over a decade.
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